DHA may inhibit B-cell differentiation into plasma cells by modulating effector CD4+ T cells, potentially through the regulation of HIF1α and ligand–receptor interactions, enhancing our understanding of DHA’s mechanisms in SLE treatment. The gene discussed is HIF1A; the disease is systemic lupus erythematosus.